Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cogstate Ltd ( (AU:CGS) ) has shared an announcement.
Cogstate Ltd announced that all resolutions were passed at its 2025 Annual General Meeting, including the re-election of directors and the renewal of the Employee Equity Plan. This outcome reflects strong shareholder support and may positively impact the company’s strategic initiatives and governance, reinforcing its position in the neuroscience technology industry.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company that specializes in optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and supports partners in delivering electronic clinical outcome assessment solutions. Cogstate has been supporting biopharmaceutical companies, academic institutions, and healthcare providers with digital cognitive measures for over 20 years.
Average Trading Volume: 181,386
Technical Sentiment Signal: Buy
Current Market Cap: A$410.9M
See more data about CGS stock on TipRanks’ Stock Analysis page.